Junzheng Group invested 1.12 billion yuan in Da'an pharmaceutical to enter the field of blood products!

Junzheng group announced today that Shengtai Information Technology Development Co., Ltd., a wholly-owned holding company of Lhasa Economic and Technological Development Zone (hereinafter referred to as "Lhasa Shengtai"), intends to subscribe for an additional capital contribution of 357.1429 million yuan from Hebei Da'an Pharmaceutical Co., Ltd (hereinafter referred to as "Da'an pharmaceutical"), with a corresponding investment amount of 112, 1.9987 million yuan, accounting for 31.17% of the registered capital of Da'an pharmaceutical after this capital increase and share expansion The evaluation / valuation of Da'an pharmaceutical has not been determined yet The tentative valuation of Da'an pharmaceutical in this transaction is RMB 2.1 billion, which corresponds to about 35.29 times of the net profit of Da'an pharmaceutical in 2018 The valuation of Da'an pharmaceutical after the completion of the previous capital increase is about RMB 1.939 billion, which may pose a higher valuation risk Gongjunzheng group's main business is the production and sale of chemical products Daan pharmaceutical is mainly engaged in the production and sale of blood products There are great differences between the two industries The capital increase of Daan Pharmaceutical by Junzheng group this time belongs to cross industry investment, which may have certain investment risks Da'an pharmaceutical's net profit in the first three quarters of 2019 was 13.9118 million yuan, a large decline compared with 59.4993 million yuan in the whole year of 2018 There is a risk that Da'an pharmaceutical's operating performance will decline significantly in the whole year After the capital increase, the equity structure of Da'an in Hebei will be as follows: Mengmeng